Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 4/20 | 0.59 |
| ▸ | MEN1 | O00255 | 2/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
| ▸ | HTR7 | P34969 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3773978 | 0.99 | POLB (0.60) | POLBMEN1KMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL3762865 | 0.97 | POLB (0.61) | POLBMEN1KMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL3769215 | 0.87 | ME2 (0.54) | MEN1KMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL3777242 | 0.86 | MEN1 (0.55) | MEN1KMT2AALDH1A1 | |
| SCHEMBL3773996 | 0.86 | KDM2B (0.51) | POLBMEN1KMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL3763137 | 0.86 | ME2 (0.55) | MEN1KMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL3773736 | 0.85 | MEN1 (0.72) | POLBMEN1KMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL13004965 | 0.85 | MEN1 (0.56) | MEN1KMT2AALDH1A1 | |
| SCHEMBL26706279 | 0.84 | ALDH1A1 (0.76) | POLBKMT2AALDH1A1SMN1; SMN2HTR7 | |
| SCHEMBL26706278 | 0.84 | ALDH1A1 (0.76) | POLBKMT2AALDH1A1SMN1; SMN2HTR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7851474-B2 | Dipiperazinyl ketones and related analogues | NEUROGEN CORPORATION (US) | 2010-12-14 | — | — | US | disclosed |
| US-7851474-B2 | Dipiperazinyl ketones and related analogues | NEUROGEN CORPORATION (US) | 2010-12-14 | — | — | US | disclosed |
| US-20070049571-A1 | Dipiperazinyl ketones and related analogues | NEUROGEN CORPORATION | 2007-03-01 | — | — | US | disclosed |
| US-20070049571-A1 | Dipiperazinyl ketones and related analogues | NEUROGEN CORPORATION | 2007-03-01 | — | — | US | disclosed |
| WO-2007016496-A2 | DIPIPERAZINYL KETONES AND RELATED ANALOGUES | NEUROGEN CORPORATION (US) | 2007-02-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070049571-A1 | Dipiperazinyl ketones and related analogues | HRH4, HRH3, HRH1 | POLB 4363/4885MEN1 3270/4885KMT2A 242/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.